Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label study of BAY 2927088 in EGFR- and/or HER2-mutant advanced non-small cell lung cancer
CTR20220141Phase 2Active
- Sponsor
- Bayer
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Started Oct 2022; status: active.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220141.